Latest Derivatives News

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

Harvest Technology Group’s half-year report reveals a 50% revenue decline and a widening net loss, offset by a $6 million funding facility and strategic partnerships.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

Change Financial has reported a strong first half for FY26 with record revenue growth and its first-ever half-year profit, underpinned by expanding recurring revenues and operational efficiencies.

TPC Consolidated Limited reported a 4.1% revenue increase to $103.6 million and a 62% jump in underlying EBITDA for the half-year ended December 2025, while the proposed acquisition scheme faces regulatory hurdles.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.

Orthocell Limited has reported a record half-year revenue of $6.2 million, driven by accelerating sales of its regenerative medicine products and expanding global footprint. The company’s US commercial launch of Remplir™ is gaining momentum alongside new market entries in Canada, Hong Kong, and Europe.

Perennial Investment Management has launched the Ziller Global Fund Active ETF (ASX: ZILR), targeting high-growth global companies led by exceptional founders. The fund aims to deliver absolute returns above the MSCI All Country World Index over a typical five-year horizon.

Cadence Capital Limited has reported a remarkable turnaround with a 508% surge in profit after tax for the half-year ended December 2025, alongside a fully franked interim dividend declaration.

Eclipse Metals reports promising Phase 1 metallurgical test results from its Grønnedal Rare Earth Element Project in Greenland, highlighting over 90% REE recovery in magnetic fractions. These findings lay the groundwork for further optimisation and scale-up testing.

BPH Global is nearing completion of its novel seaweed-based men’s health supplement, Project Popeye, as it moves toward TGA listing and scientific validation.